Novo Nordisk's (NVO) obesity therapy Wegovy cut adverse kidney-related events by 22% in obese and overweight individuals in a ...

LONDON, May 14 (Reuters) - Patients taking Novo Nordisk's popular Wegovy obesity treatment maintained an average of 10% weight loss after four years on the treatment, the company said on Tuesday. Novo ...

The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk's case to insurers and governments to ...

The data could potentially bolster Novo's case for Wegovy as it attempts to convince insurers and governments to cover the ...

Presented at this week’s European Congress on Obesity, the two studies also demonstrate that Novo Nordisk’s Wegovy ...

LONDON (Reuters) -Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four ...

New analyses of the longest clinical trial yet of the weight-loss drug Wegovy are shedding light on how quickly it helps ...

Patients taking Novo Nordisk's obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis from the longest clinical trial to date on the treatment.

Semaglutide medications including Ozempic and Wegovy have been shown to reduce kidney failure risk and the risk of death ...

In a letter to Bernie Sanders, Novo Nordisk said it only retains 60% of the list price of either Ozempic or Wegovy ...

Novo Nordisk (NVO) stock was trading down Thursday despite strong first quarter results, beating Wall Street consensus, led by the blockbuster GLP-1s Ozempic for diabetes and Wegovy for weight loss.